CAPVAXIVE 65 ug/.5mL

CAPVAXIVE 65 ug/0.5mL is a pneumococcal 21-valent conjugate vaccine designed to help prevent pneumococcal disease. This intramuscular injection is suitable for adults aged 18 and older, offering protection against 21 serotypes of Streptococcus pneumoniae.

CAPVAXIVE is a vaccine used to help prevent pneumococcal disease caused by Streptococcus pneumoniae. It is designed for adults aged 18 and older, targeting 21 serotypes of the bacterium. This vaccine is administered intramuscularly and is intended to provide immunity against pneumococcal infections, which can lead to serious conditions such as pneumonia, bacteremia, and meningitis. The primary use of CAPVAXIVE is to reduce the risk of these infections in eligible individuals.

Common effects of CAPVAXIVE may include mild to moderate reactions at the injection site, such as pain, redness, or swelling. Some individuals may experience systemic effects like fatigue, headache, or muscle pain. These effects are generally temporary and resolve within a few days. Severe allergic reactions are rare but possible and require immediate medical attention.

CAPVAXIVE should be administered by healthcare professionals. Individuals with a history of severe allergic reactions to any component of the vaccine should avoid its use. It is important to inform the healthcare provider about any current illnesses or medications before receiving the vaccine. Proper storage and handling are crucial to maintain the vaccine's effectiveness.

CAPVAXIVE may interact with other medications or vaccines. It is advisable to discuss any current medications or recent vaccinations with a healthcare provider before receiving CAPVAXIVE. Alcohol and certain immunosuppressive drugs might affect the vaccine's efficacy, so it is important to consider these factors when planning vaccination.